Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

 Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

Shots:

  • Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. Gilead acquires exclusive WW rights to develop and commercialize novel small molecules against three undisclosed targets
  • The focus of the agreement is to develop therapies for treat human rhinovirus, influenza and herpes viruses with limited therapeutic options, further improving QoL  
  • Biktarvy (qd) is an INSTI-based triple-therapy STR combining bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (BIC/FTC/TAF) approved for HIV-1 Infection in Japan. Additionally, Gilead has an antiviral portfolio which includes therapies for HIV, hepatitis B and hepatitis C, as well as influenza infection

Click here to read full press release/ article | Ref: Gilead | Image: Leo Associates

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post